The long noncoding RNA smooth muscle-induced LncRNA modulates RhoA/ROCK signaling in PAH, suggesting that the smooth muscle-induced LncRNA may be a promising and novel therapeutic target for the treatment of PAH [75]. This evidence concerns the gene RHOA and pulmonary arterial hypertension.